New imaging agent could sharpen prostate cancer staging
NCT ID NCT03535831
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed registry study at Princess Margaret Cancer Centre tested whether a special PET scan tracer called 18F-DCFPyL (PSMA) can find prostate cancer that has spread to lymph nodes or other organs better than standard CT and bone scans. A total of 142 men with intermediate- or high-risk prostate cancer, or those with a rising PSA after treatment, received a PSMA PET scan. The goal was to see if this imaging method changes how doctors stage or restage the disease and guides treatment choices.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 18F-DCFPyL (a radioactive tracer used in PET scans)
- What this could lead to
- If successful, this imaging method could help doctors find prostate cancer spread more accurately, leading to better treatment decisions.
- What could go wrong
- This is a registry study, not a randomized trial, so results may not prove that PSMA PET improves patient outcomes. The sample size is modest (142 men), and findings may not apply to all prostate cancer patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA OF PROSTATE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada